|
ÀÎÆ÷ºê·¹ÀÎ |
±¹³»À¯¸í ÀÇ·á±â±â ¾÷ü ÀÇ·á±â±â ȸ·Î¼³°è´ã´ç (»ç¿ø-°úÀå
ÃæºÏ ÃæÁֽà | ´ëÇÐ(2~3³â) Á¹¾÷ |
°ø¹«/Àü±â/±â°è |
2³â¡è |
ä¿ë½Ã |
09.16 |
|
|
¸Æ½ºÈ£¶óÀÌÁð |
±¹³» À¯¸í ÀÇ·áÀç´Ü ¿¬±¸¼Ò (Medical Project Strategist)
¼¿ï ÀüÁö¿ª | ´ëÇÐ(2~3³â) Á¹¾÷ |
|
3³â¡è |
ä¿ë½Ã |
03.31 |
|
|
¿¡À̽ºÆÄÆ®³Ê½º |
±¹³» Á¦¾àȸ»ç RA
¼¿ï ÀüÁö¿ª | ´ëÇÐ(2~3³â) Á¹¾÷ |
°³¹ß/RA/´ë°ü |
5³â¡è |
ä¿ë½Ã |
02.18 |
|
|
(ÁÖ)½áÄ¡Æ÷¸®´õ½º |
CRA, RA¸ðÁý (ÇìµåÇåÅÍÁøÇà)
¼¿ï °³²±¸ | ´ëÇÐ(2~3³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
2³â¡è |
ä¿ë½Ã |
10.07 |
|
|
(ÁÖ)¿¡ÀÌÄ¡¿¥¾¾³×Æ®¿÷½º |
º´ÀÇ¿ø ¿µ¾÷ÀÇ ½ÅÀ» ¸ð½Ê´Ï´Ù. 2014 ½ÃÁð2. ¾÷°èÃÖ°í´ë¿ìº¸
¼¿ï ÀüÁö¿ª | Çз¹«°ü |
Á¦¾à¿µ¾÷/ÀÇ·á±â¿µ¾÷ |
5³â¡è |
»ó½Ãä¿ë |
09.12 |
|
|
ÀÎÆ÷ºê·¹ÀÎ |
±¹³»À¯¸í ÀÇ·á±â±â¾÷ü ÀÇ·á±â±â ±â±¸¼³°èÀÚ (»ç¿ø-°úÀå±Þ)
ÃæºÏ ÃæÁֽà | ´ëÇÐ(2~3³â) Á¹¾÷ |
°ø¹«/Àü±â/±â°è |
2³â¡è |
ä¿ë½Ã |
09.16 |
|
|
Æ÷Ƽ½ºÆÄÆ®³Ê½º |
¿Ü±¹°è Á¦¾à»ç ¸¶ÄÉÆà alliance mgr ä¿ë
¼¿ï ÀüÁö¿ª | ´ëÇÐ(2~3³â) Á¹¾÷ |
¸¶ÄÉÆÃ/±âȹ/±³À° |
4³â¡è |
ä¿ë½Ã |
09.16 |
|
|
Ç»ÃÄ¿þÀÌ |
ÀÇ·á±â±â ¿µ¾÷ ´ã´çÀÚ
¼¿ï ÀüÁö¿ª | ´ëÇÐ(2~3³â) ÀçÇÐ |
Á¦¾à¿µ¾÷/ÀÇ·á±â¿µ¾÷ |
7³â¡è |
ä¿ë½Ã |
05.26 |
|
|
Çѱ¹ÆúÁÖ½Äȸ»ç |
Biopharmaceutical Sales Engineer for Chromatography Prod
¼¿ï °³²±¸ | ´ëÇÐ(2~3³â) Á¹¾÷ |
Á¦¾à¿µ¾÷/ÀÇ·á±â¿µ¾÷ |
4³â¡è |
»ó½Ãä¿ë |
12.11 |
|
|
InnoHR |
¼¼°èÀûÀÎ ¸ÞµðÄà ±×·ì RA Specialist
°æ±â ¼º³²½Ã ºÐ´ç±¸ | ´ëÇÐ(2~3³â) Á¹¾÷ |
°³¹ß/RA/´ë°ü |
2³â¡è |
ä¿ë½Ã |
04.18 |
|
|
ÆÄ·º¼¿ ÄÚ¸®¾Æ |
ÆĶô¼¿ ÄÚ¸®¾Æ -CRA & Dedicated CRA
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
1³â¡è |
ä¿ë½Ã |
10.26 |
|
|
ÆÄ·º¼¿ ÄÚ¸®¾Æ |
Dedicated CRA / CRA ¸ðÁý -ÆĶô¼¿ÄÚ¸®¾Æ
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
1³â¡è |
ä¿ë½Ã |
07.16 |
|
|
(ÁÖ)KDC³×Æ®¿÷½º |
ÇÁ·ÎÁ§Æ® ÃÑ°ý ¸Å´ÏÀú(Sr.CRA ÀÌ»ó °æ·Â)
¼¿ï ÀüÁö¿ª | Çз¹«°ü |
CRA/ÀÓ»óPM/CRM |
5³â¡è |
ä¿ë½Ã |
02.28 |
|
|
º£½ºÆ®³×Æ®¿öÅ©(ÁÖ) |
Pharmacovigilance(drug safety) Specialist / ¿Ü±¹°è Á¦¾à
¼¿ï °³²±¸ | ´ëÇÐ(2~3³â) Á¹¾÷ |
¸¶ÄÉÆÃ/±âȹ/±³À° |
2³â¡è |
ä¿ë½Ã |
05.14 |
|
|
(ÁÖ)ÇÇÇþØÄ¿¸®¾î±×·ì |
CRA °æ·ÂÀÚ ¸ðÁý
¼¿ï ÀüÁö¿ª | ´ëÇÐ(2~3³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
1³â¡è |
ä¿ë½Ã |
04.26 |
|